Company profile
Suzhou Alphamab
China antibody-engineering biotech (mAbs, fusion proteins, bispecifics) -- private parent entity distinct from the HKEX-listed spinout Alphamab Oncology (9966.HK)
Privately held: no public share price · China
Assets
(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | PD-L1Monoclonal antibody | HIVNon-Small Cell Lung Cancer | |
| Phase 1 | Factor XI/XIa (FXI/FXIa)Monoclonal antibody | Hypertension |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.